Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …

Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A
hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene …

In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode
four highly homologous proteins. RAS proteins are small GTPases involved in a broad …

Pancreatic cancer is a disease that has a very high fatality rate and one of the highest
mortality ratios among all major cancers, remaining the fourth leading cause of cancer …

We used whole-genome and transcriptome sequencing to identify clinically actionable
genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC) …

Biliary tract carcinomas (BTCs) are among the most aggressive malignancies and have a
poor prognosis. Here, we successfully established organoid lines derived from intrahepatic …

OBJECTIVES: There is no molecular biomarker available in the clinical practice to assess
the prognosis of advanced pancreatic carcinoma. This multicenter prospective study aimed …

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …